SoftOx is developing a range of products that can be classified as either medical devices or medicinal products (drugs) for human use. Collectively, our research and development efforts focus on the prevention and eradication of serious infections. Such infections are not limited to pathogenic bacteria, but may also include viral and fungal infections. Our current product candidates are either in the clinical or late pre-clinical (animal testing) phase.
The aim of this randomized controlled trial was to evaluate the wound-healing effect and antimicrobial properties of a novel stabilized hypochlorous acid solution on acute wounds, using a suction blister wound model.
A first-in-man, prospective, open-label, exploratory pilot study to document the preliminary safety and performance of HOCl+buffer for topical use when used on acute wounds.